- E. Coli Fears Spur Recall of 167,000 Pounds of Ground Beef
- Weight-Loss Drug Zepbound May Lower Heart Failure Deaths
- Nearly 160 Million Americans Harmed by Another’s Drinking, Drug Use
- 1 in 4 Americans Now Struggling to Cover Medical Costs
- Getting Fitter Can Really Help Keep Dementia at Bay
- Skin Patch Could Monitor Your Blood Pressure
- There May Be a Better Way to Treat Hematoma Brain Bleeds
- Chronic Joint Pain Plus Depression Can Take Toll on the Brain
- Living in Space Won’t Permanently Harm Astronauts’ Thinking Skills
- Kids’ Injuries in Sports and at Home: When Is It Right to Seek Medical Attention?
Screening Test Approved for Viruses That Cause Blood Cancer
A new screening test to detect Human T-Cell Lymphotropic viruses that cause a rare blood cancer has been approved by the U.S. Food and Drug Administration.
The viruses, abbreviated HTLV-I/II, cause diseases such as adult T-cell leukemia/lymphoma (blood cancer) and myelopathy (inflammation of spinal cord nerves) , the FDA said in a news release. HTLV can be transmitted via breastfeeding, unprotected sex or blood transfusion.
The newly approved test — MP Diagnostics HTLV Blot 2.4 — is meant to supplement existing screening for the viruses, the FDA said. The diagnostic also can differentiate between the two types, HTLV-I or HTLV-II.
Many people infected with HTLV may not be aware of its presence, since the virus does not always trigger symptoms. An infected person can transmit the virus without showing any signs or symptoms, the agency said.
The new test is produced by a Singapore subsidiary of MP Biomedicals, based in Santa Ana, Calif.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.